We are live on ! Find out more
AAA

Affinity Asset Advisors Portfolio holdings

AUM $1.94B
1-Year Est. Return 374.45%
This Fund
S&P 500
This Quarter Est. Return
+11.92%
1 Year Est. Return
+374.45%
3 Year Est. Return
+1,279.72%
5 Year Est. Return
+2,528.28%
10 Year Est. Return
–
AUM
$303M
AUM Growth
+$48M
Cap. Flow
+$31.8M
Cap. Flow %
10.49%
Top 10 Hldgs %
45.97%
Holding
88
New
25
Increased
24
Reduced
13
Closed
14

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$13M
2
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$8.63M
3
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$6.27M
4
CYTK icon
Cytokinetics
CYTK
+$5.46M
5
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$4.84M

Top Sells

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$5.7M
2
MORF
Morphic Holding, Inc. Common Stock
MORF
+$5.34M
3
ESTA icon
Establishment Labs
ESTA
+$5.32M
4
RCKT icon
Rocket Pharmaceuticals
RCKT
+$5.05M
5
NARI
Inari Medical, Inc. Common Stock
NARI
+$4.2M

Sector Composition

Rank Sector Weight
1 Healthcare 79.49%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AZN icon
26
CALL
AstraZeneca
AZN
$255B
$3.47M 1.15%
+25,000
New +$3.36M
XENE icon
27
Xenon Pharmaceuticals
XENE
$6.38B
$3.22M 1.06%
90,000
+40,000
+80% +$1.48M
ETNB
28
DELISTED
89bio
ETNB
$3.05M 1.01%
+200,000
New +$2.61M
CNTA
29
DELISTED
Centessa Pharmaceuticals
CNTA
$2.63M 0.87%
684,127
+223,799
+49% +$819K
VRDN icon
30
CALL
Viridian Therapeutics
VRDN
$2.05B
$2.56M 0.84%
+100,500
New +$3.22M
LNTH icon
31
Lantheus
LNTH
$6.8B
$2.5M 0.82%
30,244
-30,386
-50% -$1.96M
BMRN icon
32
BioMarin Pharmaceuticals
BMRN
$11.4B
$2.43M 0.8%
25,000
-55,000
-69% -$5.7M
NVAX icon
33
PUT
Novavax
NVAX
$1.3B
$2.4M 0.79%
346,800
+146,800
+73% +$1.35M
PCVX icon
34
Vaxcyte
PCVX
$8.01B
$2.33M 0.77%
62,223
+2,223
+4% +$94.3K
APLS
35
DELISTED
Apellis Pharmaceuticals
APLS
$2.31M 0.76%
+35,000
New +$2.02M
MIRM icon
36
Mirum Pharmaceuticals
MIRM
$7.11B
$2.28M 0.75%
95,000
+55,000
+138% +$1.25M
KRTX
37
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$2.27M 0.75%
+12,500
New +$2.39M
HZNP
38
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$2.18M 0.72%
20,000
-25,000
-56% -$2.76M
ALPN
39
DELISTED
Alpine Immune Sciences Inc
ALPN
$1.91M 0.63%
247,891
– –
CLDX icon
40
Celldex Therapeutics
CLDX
$2.78B
$1.8M 0.59%
50,000
-60,000
-55% -$2.59M
KPTI icon
41
Karyopharm Therapeutics
KPTI
$169M
$1.79M 0.59%
30,732
-13,352
-30% -$659K
KALV
42
DELISTED
KalVista Pharmaceuticals
KALV
$1.64M 0.54%
208,292
+20,000
+11% +$149K
VKTX icon
43
PUT
Viking Therapeutics
VKTX
$4.22B
$1.56M 0.52%
+93,900
New +$970K
VINC
44
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
$1.55M 0.51%
74,639
– –
COGT icon
45
Cogent Biosciences
COGT
$6.54B
$1.54M 0.51%
143,064
-50,000
-26% -$640K
NRIX icon
46
Nurix Therapeutics
NRIX
$2.36B
$1.33M 0.44%
150,000
+70,000
+88% +$729K
LIAN
47
DELISTED
LianBio American Depositary Shares
LIAN
$1.27M 0.42%
650,000
– –
NARI
48
DELISTED
Inari Medical, Inc. Common Stock
NARI
$1.23M 0.41%
20,000
-70,000
-78% -$4.2M
ADCT icon
49
ADC Therapeutics
ADCT
$160M
$1.17M 0.39%
+600,000
New +$2.21M
PNT
50
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$1.09M 0.36%
149,586
-153,632
-51% -$1.14M
1
2
3 4

Similar funds

FM
Foster & Motley Cincinnati, Ohio $1.94B AUM 21.65% 1-Year Est. Return
1SB
1ST Source Bank South Bend, Indiana $1.94B AUM 20.3% 1-Year Est. Return
HCL
Heard Capital LLC Chicago, Illinois $1.93B AUM 21.66% 1-Year Est. Return
OCM
Osterweis Capital Management San Francisco, California $1.94B AUM 20.77% 1-Year Est. Return
MWA
Midland Wealth Advisors Effingham, Illinois $1.94B AUM 14.31% 1-Year Est. Return
AF
Advisornet Financial Minnetonka, Minnesota $1.93B AUM 18.43% 1-Year Est. Return
NFG
Nations Financial Group Cedar Rapids, Iowa $1.94B AUM 25.76% 1-Year Est. Return
HC
Hamilton Capital Columbus, Ohio $1.93B AUM

Affinity Asset Advisors's Q1 2023 Portfolio in Review

As of Q1 2023, Affinity Asset Advisors held 88 positions worth $303M, up 19% from $255M the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Affinity Asset Advisors deployed $31.8M of net new capital in Q1 2023, opening 25 new positions and adding to 24 existing holdings. Its largest new stake was Merck: 120,000 shares worth $12.8M.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, down from 81% a quarter earlier.

On the sell side, the largest reduction was BioMarin Pharmaceuticals, an estimated $5.7M trimmed.

  • Affinity Asset Advisors's largest Q1 2023 buy was Merck: 120,000 shares worth $12.8M.
  • Affinity Asset Advisors added most to Prometheus Biosciences, Inc. Common Stock in Q1 2023, an estimated $8.63M increase.
  • Affinity Asset Advisors's biggest Q1 2023 reduction was BioMarin Pharmaceuticals, cutting an estimated $5.7M.
  • Affinity Asset Advisors fully exited Rocket Pharmaceuticals in Q1 2023, selling an estimated $5.05M.
  • Affinity Asset Advisors's ten largest holdings make up 46% of its $303M portfolio in Q1 2023.
  • Affinity Asset Advisors opened 25 new positions and closed 14 in Q1 2023.
  • Affinity Asset Advisors's portfolio value rose 19% quarter-over-quarter to $303M.

Based on Affinity Asset Advisors's 13F filing for Q1 2023, filed 15 May 2023.